Insider Trading History of Shah Preetam

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Shah Preetam since 2019. This trader's CIK number is 1787403. At the time of last reporting, Shah Preetam was the CFO & CBO of Cidara Therapeutics, Inc.. (stock ticker symbol CDTX). Also see all insider trading activities at Cidara Therapeutics, Inc..

Note that in the past Shah Preetam also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Brainstorm Cell Therapeutics Inc. (BCLI) by Shah Preetam

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 BCLI 11,600 $45,924 0 $0 0 $0

Yearly summary of insider trading at Cidara Therapeutics, Inc. (CDTX) by Shah Preetam

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 CDTX 0 $0 18,931 $12,683 0 $0
2023 CDTX 0 $0 6,648 $10,171 0 $0
2022 CDTX 0 $0 15,642 $12,028 50,000 $0
2021 CDTX 20,000 $30,800 0 $0 0 $0


Insider trading activities at 2 companies by Shah Preetam:

1. Brainstorm Cell Therapeutics Inc. (BCLI)

2. Cidara Therapeutics, Inc. (CDTX)

Table 1. Insider trading of Brainstorm Cell Therapeutics Inc. (BCLI) by Shah Preetam

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-12-24 BCLI Buy 11,600 3.96 45,924

Table 2. Insider trading of Cidara Therapeutics, Inc. (CDTX) by Shah Preetam

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-03-11 CDTX Sale 18,931 .67 12,683
2023-03-13 CDTX Sale 6,648 1.53 10,171
2022-09-15 CDTX Option Ex 50,000 .00 0
2022-09-19 CDTX Sale 15,642 .77 12,028
2021-11-12 CDTX Buy 20,000 1.54 30,800

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Shah Preetam (CFO & CBO of Cidara Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.